Philip R Yearian, DPM | |
7308 Bridgeport Way W, Suite 201, Lakewood, WA 98499-8000 | |
(253) 582-7257 | |
(253) 582-1617 |
Full Name | Philip R Yearian |
---|---|
Gender | Male |
Speciality | Podiatry |
Experience | 31 Years |
Location | 7308 Bridgeport Way W, Lakewood, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255307807 | NPI | - | NPPES |
346704 | Other | WA | WA STATE LNI |
1005973 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | P000000535 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Tacoma General Allenmore Hospital | Tacoma, WA | Hospital |
St Anthony Hospital | Gig harbor, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Proliance Surgeons Inc Ps | 8527972900 | 388 |
News Archive
In a paper published in the current issue of Psychotherapy and Psychosomatics, Giovanni Fava and Chiara Rafanelli analyze the literature concerned with iatrogenic disorders in psychiatry, which may be due to medications or psychotherapy.
Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").
More scientific research into the metabolism of stromal support cells and immune cells - and the role of the metabolism of these cell types in the development of diseases - could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature.
A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an "oncoprotein" that binds to RNA and promotes tumor growth.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
› Verified 1 days ago
Provider Name | Proliance Surgeons Inc Ps |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1023170313 PECOS PAC ID: 8527972900 Enrollment ID: O20031119000128 |
News Archive
In a paper published in the current issue of Psychotherapy and Psychosomatics, Giovanni Fava and Chiara Rafanelli analyze the literature concerned with iatrogenic disorders in psychiatry, which may be due to medications or psychotherapy.
Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").
More scientific research into the metabolism of stromal support cells and immune cells - and the role of the metabolism of these cell types in the development of diseases - could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature.
A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an "oncoprotein" that binds to RNA and promotes tumor growth.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Philip R Yearian, DPM 805 Madison St, Suite 901, Seattle, WA 98104-1172 Ph: (206) 264-8100 | Philip R Yearian, DPM 7308 Bridgeport Way W, Suite 201, Lakewood, WA 98499-8000 Ph: (253) 582-7257 |
News Archive
In a paper published in the current issue of Psychotherapy and Psychosomatics, Giovanni Fava and Chiara Rafanelli analyze the literature concerned with iatrogenic disorders in psychiatry, which may be due to medications or psychotherapy.
Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").
More scientific research into the metabolism of stromal support cells and immune cells - and the role of the metabolism of these cell types in the development of diseases - could open new therapeutic avenues for diabetes, inflammatory conditions and cancer. That was the conclusion of a review article by scientists from VIB and KU Leuven in the leading journal Nature.
A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an "oncoprotein" that binds to RNA and promotes tumor growth.
The International Association for the Study of Lung Cancer commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced non-small cell lung cancer (NSCLC) patients with a specific epidermal growth factor receptor (EGFR) mutation (T790M) and following progression after previous EGFR inhibitor therapies.
› Verified 1 days ago
Dr. Kurt Gustavson, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6216 Whisper Ln Sw, Lakewood, WA 98499 Phone: 253-968-1613 | |
Chad Farley, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 11307 Bridgeport Way Sw, Ste 220a, Lakewood, WA 98499 Phone: 253-985-2733 Fax: 253-985-3868 | |
Dr. Gavin Hall Smith, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 7308 Bridgeport Way W, Suite 201, Lakewood, WA 98499 Phone: 253-582-7257 Fax: 253-582-0687 | |
Dr. Barney Aaron Yanklowitz, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: Vapshcs ( A-112-pod ), 6900 Veterans Dr. , Sw, Lakewood, WA 98493 Phone: 253-582-8440 Fax: 253-583-1199 | |
Custer Foot And Ankle Clinic Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 7507 Custer Rd W, Lakewood, WA 98499 Phone: 253-472-6530 Fax: 253-472-6693 |